D-dimer Levels in Predicting Severity of Infection and Outcome in Patients with COVID-19.

Q3 Medicine
Tanaffos Pub Date : 2022-04-01
Mehrdad Esmailian, Zohreh Vakili, Mohammad Nasr-Esfahani, Farhad Heydari, Babak Masoumi
{"title":"D-dimer Levels in Predicting Severity of Infection and Outcome in Patients with COVID-19.","authors":"Mehrdad Esmailian,&nbsp;Zohreh Vakili,&nbsp;Mohammad Nasr-Esfahani,&nbsp;Farhad Heydari,&nbsp;Babak Masoumi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>COVID-19 disease began to spread all around the world in December 2019 until now; and in the early stage it may be related to high D-dimer level that indicates coagulation pathways and thrombosis activation that can be affected by some underlying diseases including diabetes, stroke, cancer, and pregnancy and it also can be associated with Chronic obstructive pulmonary disease (COPD). The aim of this article was to analyze D-dimer levels in COVID-19 patients, as D-dimer level is one of the measures to detect the severity and outcomes of COVID-19. According to the results of this study, there is a higher level of D-dimer as well as concentrations of fibrinogen in the disease onset and it seems that the poor prognosis is linked to a 3 to 4-fold increase in D-dimer levels. It is also shown that 76% of the patients with ≥1 D-dimer measurement, had elevated D-dimer and were more likely to have critical illness than those with normal D-dimer. There was an increase in the rates of adverse outcomes with higher D-dimer of more than 2000 ng/mL and it is associated with the highest risk of death at 47%, thrombotic event at 37.8%, and critical illness at 66%. It also found that diabetes and COPD had the strongest association with death in COVID-19. So, it is necessary to measure the D-dimer levels and parameters of coagulation from the beginning as well as pay attention to comorbidities that can help control and management of COVID-19 disease.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/0e/Tanaffos-21-419.PMC10423863.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tanaffos","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

COVID-19 disease began to spread all around the world in December 2019 until now; and in the early stage it may be related to high D-dimer level that indicates coagulation pathways and thrombosis activation that can be affected by some underlying diseases including diabetes, stroke, cancer, and pregnancy and it also can be associated with Chronic obstructive pulmonary disease (COPD). The aim of this article was to analyze D-dimer levels in COVID-19 patients, as D-dimer level is one of the measures to detect the severity and outcomes of COVID-19. According to the results of this study, there is a higher level of D-dimer as well as concentrations of fibrinogen in the disease onset and it seems that the poor prognosis is linked to a 3 to 4-fold increase in D-dimer levels. It is also shown that 76% of the patients with ≥1 D-dimer measurement, had elevated D-dimer and were more likely to have critical illness than those with normal D-dimer. There was an increase in the rates of adverse outcomes with higher D-dimer of more than 2000 ng/mL and it is associated with the highest risk of death at 47%, thrombotic event at 37.8%, and critical illness at 66%. It also found that diabetes and COPD had the strongest association with death in COVID-19. So, it is necessary to measure the D-dimer levels and parameters of coagulation from the beginning as well as pay attention to comorbidities that can help control and management of COVID-19 disease.

d -二聚体水平预测COVID-19患者感染严重程度和预后
2019年12月,新冠肺炎疫情开始在全球传播至今;在早期阶段,它可能与高d -二聚体水平有关,这表明凝血途径和血栓激活可能受到一些潜在疾病的影响,包括糖尿病、中风、癌症和妊娠,它也可能与慢性阻塞性肺疾病(COPD)有关。由于d -二聚体水平是检测COVID-19严重程度和预后的指标之一,因此本文的目的是分析COVID-19患者的d -二聚体水平。根据本研究结果,发病时d -二聚体水平和纤维蛋白原浓度较高,预后不良似乎与d -二聚体水平升高3 - 4倍有关。研究还表明,76% d -二聚体≥1的患者d -二聚体升高,比d -二聚体正常的患者更容易发生危重疾病。d -二聚体高于2000 ng/mL时,不良结局发生率增加,死亡风险最高为47%,血栓形成事件风险最高为37.8%,危重疾病风险最高为66%。研究还发现,糖尿病和慢性阻塞性肺病与COVID-19患者的死亡关系最为密切。因此,有必要从一开始就检测d -二聚体水平和凝血参数,并关注合并症,有助于COVID-19疾病的控制和管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tanaffos
Tanaffos Medicine-Critical Care and Intensive Care Medicine
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信